scispace - formally typeset
L

Luis M. Ruilope

Researcher at European University of Madrid

Publications -  891
Citations -  109166

Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.

Papers
More filters
Journal ArticleDOI

Calcium antagonists and the kidney.

TL;DR: The renal effects of different calcium antagonists on glomerular filtration rate and renal plasma flow, urinary sodium excretion, and Renni-angiotensin-aldosterone system are studied.
Journal ArticleDOI

Factors influencing return-to-work after cerebrovascular disease: the importance of previous cardiovascular risk:

TL;DR: Low CVR, along with the absence of several CVRFs, can be used to predict RTW rates following cerebrovascular events, and controlling hypertension, tobacco consumption and diabetes might contribute to the effectiveness of multidisciplinary rehabilitation and/or secondary/tertiary prevention programs for cerebroVascular disease.
Journal ArticleDOI

Effects of Antihypertensive Drugs on Blood Pressure and Metabolic Alterations in the Fructose-Induced Hypertensive Rat

TL;DR: Both quinapril and diltiazem were able to prevent BP elevation levels in the fructose-fed rat, and reduced the exaggerated response to an oral glucose tolerance test in these animals.
Journal ArticleDOI

Cicaprost, a Prostacyclin Analog, Protects Renal Function in Uninephrectomized Dogs in the Absence of Changes in Blood Pressure

TL;DR: It is suggested that cicaprost, an oral stable prostaglandin I2 analog, could have a protective renal effect in this experimental model.
Journal ArticleDOI

Public health value of fixed‐dose combinations in hypertension

TL;DR: The use of fixed-dose combinations (FDCs) for the treatment of hypertension has the potential to increase patient compliance and persistence, and may also offer equivalent or better efficacy, and the same or improved tolerability as mentioned in this paper.